Voclosporin is a next generation calcineurin inhibitor, which recently completed a Phase IIb North American trial for the prevention of kidney rejection following transplantation.
Robert Foster, Isotechnika’s chairman and CEO, said: “This completes the process, in combination with the earlier United States Adopted Names approval, of obtaining a generic name for our lead immunosuppressive drug.”